Caligan Partners LP Cuts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Caligan Partners LP decreased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 69.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 322,453 shares of the biotechnology company’s stock after selling 720,436 shares during the period. Enanta Pharmaceuticals comprises 1.1% of Caligan Partners LP’s portfolio, making the stock its 11th largest holding. Caligan Partners LP owned 1.52% of Enanta Pharmaceuticals worth $3,341,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its position in Enanta Pharmaceuticals by 4.7% in the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 1,548 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $35,000. US Bancorp DE boosted its stake in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 7,287 shares during the period. Finally, Quest Partners LLC increased its stake in Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 7,535 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on ENTA shares. Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Trading Down 2.6 %

Enanta Pharmaceuticals stock opened at $8.60 on Friday. The stock has a 50-day moving average price of $10.81 and a 200 day moving average price of $12.24. Enanta Pharmaceuticals, Inc. has a 52 week low of $8.00 and a 52 week high of $17.80.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.